埃索美拉唑治疗阿斯匹林相关性胃肠黏膜损伤62例

详细信息

收稿日期: 2013-09-29

Received Date: 29 September 2013

摘要: [目的]观察胃复春片联合西药治疗幽门螺杆菌阳性(Hp⁺)慢性胃炎脾虚兼热型的临床疗效。[方法]60例Hp⁺慢性胃炎脾虚兼热型患者随机分为2组,各30例。对照组口服泮托拉唑钠肠溶胶囊40 mg,2次/d加阿莫西林/克拉维酸钾片0.92 g,3次/d加克拉霉素缓释胶囊0.5 g,1次/d;治疗组在对照组治疗的基础上加用胃复春片1.44 g,3次/d。2组疗程均为14 d,停药至少1个月以后复查,观察2组疗效及Hp根除率等情况。[结果]治疗组症状改善明显,总有效率为90.0%,对照组为83.3%(P<0.05)。治疗组Hp根除率为90.0%,对照组为83.3%(P<0.05)。2组患者不良反应均轻微。[结论]胃复春片联合西药治疗Hp⁺慢性胃炎临床疗效显著,Hp根除率高,不良反应少。
- 阿斯匹林 /
- 胃肠黏膜损伤 /
- 埃索美拉唑 /
- 奥美拉唑

[1]	崔忠敏, 李兆申, 范群铭, 等.非甾体类抗炎药胃肠黏膜损伤流行病学及其临床特点[J].中华消化杂志, 2003, 23 (12):748-750.
[2]	陶国枢.循证应用阿斯匹林防治心脑血管疾病[J].保健医苑, 2006, (1):18-19.
[3]	冯雯, 范一宏, 吕宾.阿斯匹林对胃肠黏膜的损伤作用[J].胃肠病学, 2011, 16 (1):60-62.
[4]	BHATT D L, SCHEIMAN J, ABRAHAM N S.ACCF/ACG/AHA 2008expert consensus document on reducing the gast rointestinal risks of antiplatelett herapy and NSAID use:a report of the American college of cardiology foundation task force on clinical expert consensus documents[J].Circulation, 2008, 118:1894-1909.
[5]	LOU H Y, CHANG C C, SHEN M T, et al.Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19ploymorphism[J].Eur J Clin Pharmacol, 2009, 65:55-64.
[6]	MORGNER A, MIEHLKE S, LABENZ J.Esomprazole prevention and treatment of NSAID-induced symptoms and ulcers[J].Expert Opin Pharmacother, 2007, 8:975-988.
[7]	BLANDIZZI C, TUCCORI M, COLUCCI R, et al.Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAID in elderly patients[J].Drugs Aging, 2008, 25:197-208.
[8]	加拿大卫生部.奥美拉唑和埃索美拉唑安全性评估[J].今日药学, 2008, 18 (4):37-37.